Skip to content

Guidelines

TL;DR — Colorectal guidance is fragmented by task: screening bodies govern average-risk detection, gastroenterology societies govern polyp/hereditary surveillance, surgical societies govern operative quality and follow-up, and oncology groups govern systemic and rectal multimodality care. The strongest convergence is universal MMR/MSI testing, oncologic resection for localized disease, oxaliplatin-based therapy for fit stage III colon cancer, TNT for many higher-risk rectal cancers and biomarker-directed metastatic therapy (Morris 2023, PMID 36252154; Scott 2024, PMID 39116386). The largest disagreements concern screening test/interval preferences, stage II chemotherapy, 3 versus 6 months of stage III therapy, radiation omission, watch-and-wait implementation, germline-testing breadth and surveillance intensity. USPSTF recommends screening ages 45–75 and selective screening 76–85; blood tests were not included because outcome evidence was insufficient (US Preventive Services Task Force 2021, PMID 34003218). Guidelines age quickly in a field where BREAKWATER, CheckMate 8HW and ctDNA trials change sequences, so document year and supersession matter as much as society name.

How to read a recommendation

Element Question
Population Does the patient match stage, site, age, fitness and biomarker?
Intervention/comparator What was actually compared?
Outcome Survival, recurrence, response, function or convenience?
Evidence grade Randomized, observational, consensus or extrapolation?
Strength Must, should, may or expert option?
Date Does it predate decisive trials/approvals?
Region Are drugs, screening capacity and surgery available?

Different recommendations can both be rational when health-system capacity, accepted risk and drug access differ.

Screening guidance

USPSTF recommends screening all average-risk adults 50–75 (grade A), adults 45–49 (grade B), selective screening 76–85 (grade C) and stopping after 85. Options include annual FIT, stool DNA-FIT every 1–3 years, CT colonography every 5 years, flexible sigmoidoscopy every 5 years, sigmoidoscopy every 10 years plus annual FIT, or colonoscopy every 10 years (US Preventive Services Task Force 2021, PMID 34003218; official statement accessed 2026-08-30: https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening).

ACS moved average-risk initiation to 45 as a qualified recommendation and emphasizes test choice plus completion of diagnostic colonoscopy (Wolf 2018, PMID 29846947).

Issue Convergence Disagreement/gap
Start age 45 in current US bodies PubMed search updated through 2026-08-30 identified modeling and implementation evidence but no direct randomized CRC-mortality estimate below 50
Stop age Individualize late 70s/80s Exact life-expectancy threshold
Preferred test Any completed validated strategy Some systems prioritize FIT; others colonoscopy
Blood tests Not in 2021 USPSTF set How to incorporate after recent validation
Family history Earlier colonoscopy Degree/age-specific interval varies

NordICC’s participation-sensitive incidence effect and long flexible-sigmoidoscopy mortality data explain why guideline bodies distinguish test efficacy from strategy effectiveness (Bretthauer 2022, PMID 36214590; Wooldrage 2024, PMID 39038482).

Post-polypectomy and post-cancer colonoscopy

US Multi-Society Task Force guidance lengthens intervals after low-risk adenomas and shortens after advanced/multiple lesions; serrated features are explicitly incorporated. Evidence is largely observational.

After colorectal-cancer resection, USMSTF recommends perioperative clearing and subsequent colonoscopy, while systemic recurrence surveillance is handled separately (Kahi 2016, PMID 26892199). ESGE/ESDO similarly defines endoscopic surveillance after surgical/endoscopic resection (Hassan 2019, PMID 30722071).

Baseline finding Direction of guidance
High-quality normal colonoscopy Long interval
1–2 small tubular adenomas Longer interval than historic practice
Advanced adenoma Shorter surveillance
Large/dysplastic SSL Shorter serrated surveillance
Piecemeal large-lesion resection Early scar check
Cancer resection Perioperative clearing then scheduled colonoscopy

Residual risk studies support stratification but do not prove each exact interval (He 2020, PMID 31302144; Atkin 2017, PMID 28457708).

Pathology standards

Guidelines converge on structured reporting of site, type, grade, pT/pN, margins, node count, deposits, lymphovascular/perineural invasion, treatment response and MMR/MSI (Jass 2007, PMID 17270246).

ITBCC recommends a standardized tumor-budding hotspot of 0.785 mm² and three-tier score; budding informs pT1 nodal risk and stage II prognosis (Lugli 2017, PMID 28548122).

At least 12 nodes is the common colon-resection quality target, supported by consistent observational survival association rather than a randomized threshold (Chang 2007, PMID 17374833).

Stage II colon cancer

ASCO advises against routine adjuvant chemotherapy in low-risk stage II. T4 tumors should be offered therapy; other high-risk features justify consideration. Oxaliplatin is not routinely required and dMMR argues against fluoropyrimidine monotherapy in many stage II settings (Baxter 2022, PMID 34936379).

Feature Guideline direction Evidence weakness
T4 Strongest reason to offer Absolute benefit still individualized
<12 nodes Consider therapy Quality surrogate and stage migration
Obstruction/perforation Consider therapy Definitions vary
LVI/PNI, poor grade, budding Consider therapy Interobserver and retrospective evidence
dMMR without T4 Observation often favored Subgroup/predictive limitations
ctDNA positive Trial/structured use; rapidly evolving Escalation benefit not established

QUASAR supports a small average fluoropyrimidine benefit, while DYNAMIC supports ctDNA-guided reduction in chemotherapy without establishing every assay as standard (QUASAR Collaborative Group 2007, PMID 18083404; Tie 2022, PMID 35657320).

Stage III colon cancer and duration

Guidelines converge on fluoropyrimidine plus oxaliplatin for fit patients. IDEA makes duration risk- and regimen-specific rather than universally 3 or 6 months (André 2020, PMID 33271092).

ASCO duration guidance supports offering 6 months for T4 and/or N2 and either 3 or 6 months for T1–3 N1 after discussing recurrence and neuropathy (Lieu 2019, PMID 30986117).

Context Common guideline interpretation
Lower-risk T1–3 N1 CAPOX 3 months reasonable
High-risk T4 and/or N2 6 months favored
FOLFOX 6 months retains stronger efficacy support
Frail/neuropathy Modify or omit oxaliplatin

Rectal cancer

ASCO 2024 recommends TNT for many locally advanced tumors, especially lower rectal and/or higher-risk MRI disease; chemotherapy after radiation (consolidation) is preferred when organ preservation is a priority, and long-course chemoradiation is often preferred over short-course in that context (Scott 2024, PMID 39116386).

PROSPECT supports neoadjuvant FOLFOX with selective radiation for eligible intermediate-risk patients, not threatened-MRF/high-risk disease (Schrag 2023, PMID 37272534).

Issue Guideline convergence Ongoing disagreement
Pelvic MRI Required for local risk Upper-rectal definitions
TME Surgical standard Transanal/robotic technique and volume thresholds
TNT Standard for many high-risk tumors Short-course versus long-course backbone
Watch-and-wait Option after cCR in experienced programs Exact response/surveillance criteria
Radiation omission Selected PROSPECT-like patients Generalization and preservation tradeoff
dMMR PD-1 Transformative option in specialized care Durability and formal standardization

RAPIDO and OPRA create the central tradeoff: intensified neoadjuvant therapy can improve systemic control or preservation, but local recurrence and surveillance capacity must be included (Dijkstra 2023, PMID 36661037; Verheij 2024, PMID 37883738).

Metastatic systemic therapy

ASCO and ESMO converge on broad molecular testing, multidisciplinary resectability review, doublet/triplet selection by fitness, anti-EGFR use in left-sided RAS-wild-type disease, checkpoint therapy for MSI-high/dMMR and biomarker-directed later lines (Morris 2023, PMID 36252154; Cervantes 2023, PMID 36307056).

Biomarker/context Convergent recommendation
MSI-high/dMMR First-line checkpoint therapy
Left-sided RAS-WT Chemotherapy + anti-EGFR is preferred response/survival strategy
Right-sided RAS-WT Bevacizumab-based first line generally favored
BRAF V600E after prior therapy Encorafenib + cetuximab
HER2+, RAS-WT Dual HER2 therapy after standard lines
KRAS G12C G12C + EGFR combination where approved
Refractory unselected TAS-102 + bevacizumab or fruquintinib among options

Recent BREAKWATER and CheckMate 8HW results postdate many guideline publications and require version-level checking (Kopetz 2025, PMID 39863775; André 2025, PMID 39874977).

Metastasis-directed therapy

Guidelines agree that potentially resectable liver/lung disease needs multidisciplinary review. They disagree less on principles than on thresholds and local expertise.

Perioperative FOLFOX is an option for resectable liver metastases because it improves PFS, not because OS benefit was proven (Nordlinger 2013, PMID 24120480). New EPOC argues against perioperative cetuximab even in RAS-selected disease (Bridgewater 2020, PMID 32014119).

Lung metastasectomy recommendations rely heavily on observational selection; PulMiCC did not establish benefit (Milosevic 2020, PMID 32388895).

Hereditary guidance

ACG and BSG/ACPGBI/UKCGG provide syndrome-specific surveillance for Lynch, APC/MUTYH polyposis and hamartomatous syndromes (Syngal 2015, PMID 25645574; Monahan 2020, PMID 31780574).

Topic Convergence Variation
Universal MMR tumor testing Strong Reflex algorithm details
Lynch colonoscopy Frequent, gene-aware Start age/interval by gene
FAP surgery Before unmanageable cancer risk Operation and timing
Aspirin in Lynch Discuss/offer in many systems Dose and duration
Universal germline panels Expanding Panel breadth and age criteria

Broad unselected testing studies challenge older restrictive criteria, but VUS and cascade implementation remain concerns (Uson 2022, PMID 33857637; Coughlin 2022, PMID 36370464).

Emergency guidance

WSES guidance addresses obstruction and perforation, prioritizing resuscitation, sepsis control, oncologic safety and context-specific stent/diversion/resection choices (Pisano 2018, PMID 30123315).

Stent as bridge to surgery can reduce short-term stoma/adverse events in left-sided obstruction in randomized-trial meta-analysis, while perforation and oncologic uncertainty require expertise (Arezzo 2017, PMID 28392363).

Main disagreements and why they persist

  1. Preferred screening strategy: outcome evidence, capacity and participation differ.
  2. Stage II adjuvant treatment: absolute benefit is small and risk markers imperfect.
  3. Stage III duration: regimen-by-risk interaction plus neuropathy preferences.
  4. Rectal radiation/TNT sequence: systemic, local and functional endpoints compete.
  5. Watch-and-wait: depends on surveillance and salvage infrastructure.
  6. Germline breadth: higher yield versus VUS/cost/cascade limitations.
  7. Surveillance intensity: treatable-recurrence detection versus false positives and burden.

Open questions

  • How quickly should guideline bodies incorporate strong phase III results before mature OS? (Kopetz 2025, PMID 39863775)
  • Can ctDNA be recommended by assay and clinical action rather than as one technology class? (Tie 2022, PMID 35657320)
  • Which minimum infrastructure should be mandatory before offering watch-and-wait? (Verheij 2024, PMID 37883738)
  • Should universal germline testing replace age/family-history criteria? (Uson 2022, PMID 33857637)
  • Can cross-society surveillance recommendations converge on patient-important outcomes? (Dawood 2023, PMID 36806402)

References

  1. Morris VK, et al. Treatment of Metastatic Colorectal Cancer: ASCO Guideline. J Clin Oncol. 2023;41(3):678-700. PMID 36252154
  2. Scott AJ, et al. Management of Locally Advanced Rectal Cancer: ASCO Guideline. J Clin Oncol. 2024;42(28):3355-3375. PMID 39116386
  3. US Preventive Services Task Force, et al. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2021;325(19):1965-1977. PMID 34003218
  4. Wolf AMD, et al. Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. CA Cancer J Clin. 2018;68(4):250-281. PMID 29846947
  5. Bretthauer M, et al. Effect of Colonoscopy Screening on Risks of Colorectal Cancer and Related Death. N Engl J Med. 2022;387(17):1547-1556. PMID 36214590
  6. Wooldrage K, et al. Long-term effects of once-only flexible sigmoidoscopy screening on colorectal cancer incidence and mortality: 21-year follow-up of the UK Flexible Sigmoidoscopy Screening randomised controlled trial. Lancet Gastroenterol Hepatol. 2024;9(9):811-824. PMID 39038482
  7. Kahi CJ, et al. Colonoscopy Surveillance After Colorectal Cancer Resection: Recommendations of the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2016;150(3):758-768.e11. PMID 26892199
  8. Hassan C, et al. Endoscopic surveillance after surgical or endoscopic resection for colorectal cancer: European Society of Gastrointestinal Endoscopy (ESGE) and European Society of Digestive Oncology (ESDO) Guideline. Endoscopy. 2019;51(3):266-277. PMID 30722071
  9. He X, et al. Long-term Risk of Colorectal Cancer After Removal of Conventional Adenomas and Serrated Polyps. Gastroenterology. 2020;158(4):852-861.e4. PMID 31302144
  10. Atkin W, et al. Adenoma surveillance and colorectal cancer incidence: a retrospective, multicentre, cohort study. Lancet Oncol. 2017;18(6):823-834. PMID 28457708
  11. Jass JR, et al. Recommendations for the reporting of surgically resected specimens of colorectal carcinoma. Hum Pathol. 2007;38(4):537-545. PMID 17270246
  12. Lugli A, et al. Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016. Mod Pathol. 2017;30(9):1299-1311. PMID 28548122
  13. Chang GJ, et al. Lymph node evaluation and survival after curative resection of colon cancer: systematic review. J Natl Cancer Inst. 2007;99(6):433-41. PMID 17374833
  14. Baxter NN, et al. Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update. J Clin Oncol. 2022;40(8):892-910. PMID 34936379
  15. Quasar Collaborative Group, et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet. 2007;370(9604):2020-9. PMID 18083404
  16. Tie J, et al. Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer. N Engl J Med. 2022;386(24):2261-2272. PMID 35657320
  17. André T, et al. Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials. Lancet Oncol. 2020;21(12):1620-1629. PMID 33271092
  18. Lieu C, et al. Duration of Oxaliplatin-Containing Adjuvant Therapy for Stage III Colon Cancer: ASCO Clinical Practice Guideline. J Clin Oncol. 2019;37(16):1436-1447. PMID 30986117
  19. Schrag D, et al. Preoperative Treatment of Locally Advanced Rectal Cancer. N Engl J Med. 2023;389(4):322-334. PMID 37272534
  20. Dijkstra EA, et al. Locoregional Failure During and After Short-course Radiotherapy Followed by Chemotherapy and Surgery Compared With Long-course Chemoradiotherapy and Surgery: A 5-Year Follow-up of the RAPIDO Trial. Ann Surg. 2023;278(4):e766-e772. PMID 36661037
  21. Verheij FS, et al. Long-Term Results of Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy: The Randomized Phase II OPRA Trial. J Clin Oncol. 2024;42(5):500-506. PMID 37883738
  22. Cervantes A, et al. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(1):10-32. PMID 36307056
  23. Kopetz S, et al. Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial. Nat Med. 2025;31(3):901-908. PMID 39863775
  24. André T, et al. Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial. Lancet. 2025;405(10476):383-395. PMID 39874977
  25. Nordlinger B, et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2013;14(12):1208-15. PMID 24120480
  26. Bridgewater JA, et al. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol. 2020;21(3):398-411. PMID 32014119
  27. Milosevic M, et al. Pulmonary Metastasectomy in Colorectal Cancer: updated analysis of 93 randomized patients - control survival is much better than previously assumed. Colorectal Dis. 2020;22(10):1314-1324. PMID 32388895
  28. Syngal S, et al. ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol. 2015;110(2):223-62; quiz 263. PMID 25645574
  29. Monahan KJ, et al. Guidelines for the management of hereditary colorectal cancer from the British Society of Gastroenterology (BSG)/Association of Coloproctology of Great Britain and Ireland (ACPGBI)/United Kingdom Cancer Genetics Group (UKCGG). Gut. 2020;69(3):411-444. PMID 31780574
  30. Uson PLS, et al. Germline Cancer Susceptibility Gene Testing in Unselected Patients With Colorectal Adenocarcinoma: A Multicenter Prospective Study. Clin Gastroenterol Hepatol. 2022;20(3):e508-e528. PMID 33857637
  31. Coughlin SE, et al. Multigene Panel Testing Yields High Rates of Clinically Actionable Variants Among Patients With Colorectal Cancer. JCO Precis Oncol. 2022;6:e2200517. PMID 36370464
  32. Pisano M, et al. 2017 WSES guidelines on colon and rectal cancer emergencies: obstruction and perforation. World J Emerg Surg. 2018;13:36. PMID 30123315
  33. Arezzo A, et al. Stent as bridge to surgery for left-sided malignant colonic obstruction reduces adverse events and stoma rate compared with emergency surgery: results of a systematic review and meta-analysis of randomized controlled trials. Gastrointest Endosc. 2017;86(3):416-426. PMID 28392363
  34. Dawood ZS, et al. Colonoscopy, imaging, and carcinoembryonic antigen: Comparison of guideline adherence to surveillance strategies in patients who underwent resection of colorectal cancer - A systematic review and meta-analysis. Surg Oncol. 2023;47:101910. PMID 36806402